Introduction: Transplant ineligible patients (pts) with relapsed/refractory (R/R) FL or DLBCL have poor outcomes. Polatuzumab vedotin (pola), an antibody drug conjugate that targets delivery of the microtubule inhibitor MMAE to cells expressing CD79b, + rituximab (R) has showed promising responses in R/R FL and DLBCL. Adding bendamustine (B) to pola-R and substituting obinutuzumab (G) for R could improve outcomes. We report updated results from the Phase (P) 1b/2 study evaluating pola + BR or BG and the P2 expansion cohorts evaluating pola + BG in patients (pts) with R/R FL and DLBCL (ClinicalTrials.gov NCT02257567). Stage III/IV, 2 (1-7) median lines of prior tx, 82% refractory to last tx, 3% prior BMT.
wide. The engagement rate (patients who answered screening questions) was 6.7% and the match rate was 53 patients per month. The average time for a patient to establish eligibility and connect with a trial site and a research nurse was 13.9 hours. The average number of messages between the patient and the trial nurse was 8.6. The number of matches generated to at least one trial was 446 while 204 profiles were not matched to any of the 25 trials in the programme. 
